Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04331717
Other study ID # J1943
Secondary ID IRB00207275
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date November 16, 2020
Est. completion date December 2023

Study information

Verified date April 2022
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The standard of care for obese men starting Androgen deprivation therapy (ADT) is physician based dietary and exercise counseling. Interventions to lessen the harmful effects of ADT are needed yet have been limited. Exercise is one strategy that has been attempted however there is conflicting data as to whether or not exercise effectively improves body mass, results in sustained weight loss, improvements in metabolic risk profiles including glucose tolerance and lipid profiles in men starting ADT, or has any effect of progression of cancer. Dietary interventions have been attempted without clear improvement in weight, metabolic factors, quality of life or cancer progression. Bariatric arterial embolization (BAE), given it results in weight loss in obese men and women without cancer, may be able to stave off the harmful side effects of ADT by inducing weight loss. Therefore, the investigators hypothesize that Bariatric Arterial embolization (BAE), done prior to initiation of ADT, will mitigate the weight gain and metabolic side effects associated with ADT, by inducing weight loss of at least 5% in obese men with biochemical recurrent prostate cancer starting ADT. The primary objective is to determine if BAE, done prior to ADT initiation in obese men (with obesity related comorbid condition) with biochemically recurrent prostate cancer, can induce 5% or greater weight loss at 6 months.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2023
Est. primary completion date August 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information (HIPAA authorization will be included in the informed consent) - Males aged 18 years of age and above - Histological proof of adenocarcinoma of the prostate - Non-metastatic disease by computed tomography (CT), magnetic resonance imaging (MRI) or Nuclear medicine (NM) bone scan. Patients must have CT abdomen/pelvis with contrast prior to enrollment. - Metastatic disease may be permitted if NOT starting on any concomitant therapy (ie chemotherapy, anti-androgens) - Prior local therapy with prostatectomy or radiotherapy (including brachytherapy) or both - BMI >30 kg/m2 with a concurrent obesity related comorbidity Obesity related comorbidity is defined as: - hypertension (resting blood pressure >130/80 millimeters of mercury (mmHg) or being on medication to treat high blood pressure50), - coronary artery disease (defined as prior myocardial infarction, elevated coronary artery calcium score, positive stress test history), - dyslipidemia (triglyceride level of >150mg/dL or being on medicine to treat high triglycerides; HDL < 40mg/dL or being on medicine to treat cholesterol)51, - diabetes (fasting glucose >126mg/dL, A1c > 6.5% or on medication for diabetes)52, - pre-diabetes (fasting plasma glucose 100-125mg/dL)52, - elevated waist circumference (>40 inches in men), - obstructive sleep apnea, - arthritis, or - non-alcoholic steatohepatitis. - Prior salvage or adjuvant radiation therapy is allowed but must have been completed at least 3 months prior to enrollment - Non-castrate levels of testosterone (>50 ng/dL required) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening - Vascular anatomy (including celiac, hepatic and gastric arteries) that in the opinion of the interventional radiologist is amenable to bariatric embolization as assessed on 3D CT angiography - Participants must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below: Hemoglobin = 10.0 g/dL with no blood transfusion in the past 28 days Absolute neutrophil count (ANC) = 1.0 x 109/L Platelet count = 50 x 109/L Total bilirubin = 1.5 x institutional upper limit of normal (ULN) Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal Estimated Glomerular filtration rate (GFR) >60ml/min Exclusion Criteria: - Prior hormonal therapy within 12 months of enrollment - Planned concurrent cytotoxic chemotherapy or antiandrogens (ex. bicalutamide, abiraterone acetate, enzalutamide or any investigational agent). - Contraindication to the use of leuprolide, such as a previous hypersensitivity reaction to an Luteinizing hormone-releasing hormone (LHRH) analogue or any of the excipients in the leuprolide injection - Prior history of gastric, pancreatic, hepatic and/or splenic surgery - Prior radiation therapy to the upper abdomen (pelvic radiation is not an exclusion) - Prior embolization to the stomach, spleen or liver - Cirrhosis or known portal venous hypertension - Active peptic ulcer disease or significant risk factors for peptic ulcer disease including daily NSAID use or daily smoking - Hiatal hernia >5cm in size - Active h.pylori infection (patients will be required to have negative h.pylori testing) - Weight >400 pounds or BMI >45kg/m2 - Known aortic arch pathology such as aneurysm or dissection - Major comorbidity that precludes procedure including significant cardiovascular disease or peripheral arterial disease including the following: Myocardial infarction within 6 months before screening Unstable angina within 3 months before screening New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months before the randomization date demonstrates a left ventricular ejection fraction = 45% History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening Peripheral arterial stenting or bypass procedure within 6 months before screening Active claudication - Diabetes with A1c >7% or requiring medication other than metformin - Known gastric motility dysfunction - Preexisting chronic abdominal pain - Positive stool occult study - Inflammatory bowel disease - Known history of allergy to iodinated contrast media - American Society of Anesthesiology (ASA) physical status classification system Class 4 of 5 (very high risk surgical candidates: class 4 = incapacitating disease that is a constant threat to life) at the time of screening for enrollment - Any condition in which the principle investigator feels participation in the trial would put the patient and undue risk

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Bead Block 300-500 um
These patients will undergo embolization with 300-500µm Bead Block particles.
Behavioral:
Weight Management
All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
Drug:
Lupron
22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator

Locations

Country Name City State
United States Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Maryland Cigarette Restitution Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Time to disease progression The amount of Time (months) till prostate-specific antigen (PSA) progression which will be assessed by PSA blood test at screening, 12 weeks, 24 weeks, 36 weeks, and 48 weeks. With PSA progression defined as first PSA increase that is 25% and 2ng/mL above the nadir, and which is confirmed by a second value at least 3 weeks later, or the amount of Time till radiographic progression which will be assessed by RECIST v1.1 using conventional CT chest/abd/pelvis or NM Bone scan. Radiographic progression will be defined as visceral and nodal disease or at least 2 new bone lesions. Up to 51 weeks
Other Change in C-Reactive Protein level C-Reactive Protein (CRP) levels in mg/dL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Erythrocyte Sedimentation Rate Erythrocyte Sedimentation Rate (ESR) in millimeters per hour. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Interleukin 6 level Interleukin 6 (IL-6) levels in pg/ml. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Interleukin 8 level Interleukin 8 (IL-8) levels in pg/mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Tumor Necrosis Factor Alpha level Tumor Necrosis Factor Alpha (TNF-a) levels in pg/mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Interleukin 1 alpha level Interleukin 1 alpha (IL-1a) levels in pg/mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Interleukin 1 beta level Interleukin 1 beta (IL-1ß) levels in pg/mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Ghrelin level Ghrelin levels in pg/mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in leptin level Leptin levels in percentage. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in active Glucagon-like Peptide-1 level Active Glucagon-like Peptide-1 (GLP-1) levels in pmol/L. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Peptide YY level Peptide YY (PYY) levels in pmol/L. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Insulin-like growth factor 1 level Insulin-like growth factor 1 (IGF-1) levels in ng/mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Adiponectin level Adiponectin levels in mL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in microbiome To evaluate changes in the microbiome of men with prostate cancer before and after undergoing BAE and starting ADT. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in high density lipoprotein level High density lipoprotein (HDL) levels in mg/dL. At 12 weeks, 24 weeks, 36 weeks and 48 weeks
Other Change in triglycerides level Triglycerides level in mg/dL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in fasting glucose level Fasting glucose (mg/dL) will be assessed at specified time points for any changes. Fasting glucose within normal is <126 mg/dL. At 12 weeks, 24 weeks, 36 weeks and 48 weeks
Other Change in hemoglobin A1c level Hemoglobin A1c levels in percentage will be assessed at 12 weeks, 24 weeks, 36 weeks, and 48 weeks. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in low density lipoprotein level Low density lipoprotein (LDL) levels in mg/dL. At 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Quality of life as assessed by Abbreviated version of the medical outcomes, short-form 36 (SF-12) Quality of Life scored on a scale from 0 to 48, higher scores representing highest level of functioning possible. Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Quality of life as assessed by Impact of Weight on Quality of Life Questionnaire (IWQOL) Impact of Weight on Quality of Life all 31 questions are scored on a scale from 1 to 5, higher scores representing poorer quality of life. Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) The global PSQI score is calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality. Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Quality of life as assessed by Expanded Prostate Cancer Index Composite-26 question assessment (EPIC-26) All questions are scored on a scale from 0 to 100. The total score from all of the questions answered is divided by the total number of the questions answered yielding a global score from 0-100 with 100 representing the highest level of functioning possible. Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Other Change in Fatigue as assessed by the Brief Fatigue Inventory (BFI) Fatigue Rated by 9 each item on a 0-10 and 1 on a yes no scale, higher scores representing more fatigue. Baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Primary Number of participants who experience at least 5 percent weight loss Number of participants who experience at least 5 percent weight loss at 6 months after BAE. At 6 months
Secondary Number of adverse events Number of adverse events will be assessed to determine if there are any increased adverse events in men with prostate cancer undergoing BAE. Up to 6 months
Secondary Change in Blood Pressure Blood pressure (mmHg) will be assessed for changes over the specified time points. Baseline, weeks 4, 8, 12, 16, 20, 24, 36 and 48
Secondary Change in Respiratory Rate Respiratory rate in breaths per minute will be assessed for changes over the specified time points. Baseline, weeks 4, 8, 12, 16, 20, 24, 36 and 48
Secondary Change in Oxygen saturation Oxygen saturation (percentage) will be assessed for changes over the specified time points. Baseline, weeks 4, 8, 12, 16, 20, 24, 36 and 48
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04517591 - Reducing Sedentary Time in Bariatric: The Take a STAND for Health Study N/A
Active, not recruiting NCT04583683 - Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities N/A
Completed NCT01550601 - Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity N/A
Completed NCT03638843 - Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2 N/A
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Completed NCT03339791 - Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial N/A
Recruiting NCT05711758 - Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
Not yet recruiting NCT04209842 - Effectiveness Gastric Balloon in Obese Adolescents N/A
Recruiting NCT03100292 - Korean OBEsity Surgical Treatment Study N/A
Active, not recruiting NCT04357119 - Common Limb Length in One-anastomosis Gastric Bypass N/A
Completed NCT03210207 - Gastric Plication in Mexican Patients N/A
Completed NCT02590406 - EPO2-A: Evaluation of Pre-Oxygenation in Morbid Obesity: Effect of Position and Positive Pressure Ventilation N/A
Completed NCT01840020 - BAR-trial: Bioavailability of Ethanol Following Bariatric Surgery
Completed NCT01183975 - Swedish Adjustable Gastric Banding Observational Cohort Study N/A
Completed NCT03872024 - Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients N/A
Terminated NCT05993169 - Body Composition Optimization Intervention RCT N/A
Not yet recruiting NCT05974995 - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer N/A
Recruiting NCT05554016 - The UFO (Ultra Processed Foods in Obesity) Project
Not yet recruiting NCT05499949 - The Franciscus Obesity NASH Study
Completed NCT05519423 - Investigation of the Effectiveness of Whatsapp-Based Physical Activity Incentive Program in Morbidly Obese Individuals N/A